Literature DB >> 10364707

Correlation between cytomegalovirus infection and Raynaud's phenomenon in lupus nephritis.

P Stratta1, C Canavese, G Ciccone, S Santi, M Quaglia, V Ghisetti, G Marchiaro, A Barbui, F Fop, R Cavallo, G Piccoli.   

Abstract

Relationships between viruses and autoimmune diseases such as systemic lupus erythematosus (SLE) are still elusive. Recent reports demonstrated the association of some viral infections with peculiar clinical events in the general population, such as cytomegalovirus (CMV) with arterial damage and Parvovirus B19 (PV-B19) with hematologic abnormalities. We planned to look for this kind of viral imprinting in SLE, hypothesizing that traces of specific features of some viral infections might be found in some subsets of seropositive SLE patients. In 60 SLE patients recruited at our nephrologic center, serology for CMV, PV-B19, Epstein-Barr virus viral capsid antigen (EBV-VCA), Epstein-Barr nuclear antigen (EBNA) and Epstein-Barr virus early antigen (EBV-EA) was performed. chi2 and ANOVA were employed to compare the frequency and titers of antiviral antibodies in SLE patients with groups of transplant, hemodialysis and blood donor subjects. chi2, Fisher's test, Bonferroni and Scheffe's test were employed to compare the different biochemical/clinical features between seropositive and seronegative SLE patients. Univariate and multivariate analysis (logistic regression models) were employed to evaluate the odds ratio (OR) of different risk factors for vascular events (including Raynaud's phenomenon, deep venous thrombosis) and hematologic abnormalities (including severe anemia, leukopenia and thrombocytopenia). Anti-CMV (82%), anti-PV-B19 (60%), anti-EBV-VCA (92%) and EBV-EA (45%) IgG antibodies were frequent in SLE, with higher prevalence in comparison with the blood donor group and higher titers in comparison with transplant and hemodialysis groups. CMV seropositivity was a highly significant risk factor for Raynaud's phenomenon (OR +alpha in univariate and multivariate analysis = 13.51 using a correction of 0.5 in case of a zero event), but not for venous vascular events (OR = 1.31). An increased though not significant risk factor was found for antiphospholipid antibodies (OR = 2.71, p = 0.19), while the presence of nephrotic syndrome during the follow-up was a significant protective factor (OR = 0.15, p = 0.035). There was no significantly increased OR for PV-B19 seropositivity in cases with severe anemia (OR = 2.09, p = 0. 29). No significant associations were found with the status of EBV reactivation. In conclusion, our results support the hypothesis that viral infection may imprint the course of SLE leading to specific clinical subsets (i.e. CMV and 'vascular' SLE, with more frequent Raynaud's phenomenon and a less frequent typical histological renal picture responsible for nephrotic syndrome). Further prospective studies are justified to validate these correlations, mainly dealing with associations between acute viral infections and vascular events, thus eventually leading to a better understanding of mutual relationships between viruses and SLE.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10364707     DOI: 10.1159/000045391

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  17 in total

1.  Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice.

Authors:  M Chang; M-R Pan; D-Y Chen; J-L Lan
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

Review 2.  Infections and systemic lupus erythematosus.

Authors:  S Esposito; S Bosis; M Semino; D Rigante
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-09       Impact factor: 3.267

3.  Incidental discovery of high systemic lupus erythematosus disease activity associated with cytomegalovirus viral activity.

Authors:  Ben Yu-Jih Su; Cheng-Yu Su; Shan-Fu Yu; Chung-Jen Chen
Journal:  Med Microbiol Immunol       Date:  2007-02-23       Impact factor: 3.402

Review 4.  New trends of an old disease: the acute post infectious glomerulonephritis at the beginning of the new millenium.

Authors:  Piero Stratta; Claudio Musetti; Antonella Barreca; Gianna Mazzucco
Journal:  J Nephrol       Date:  2014-01-31       Impact factor: 3.902

Review 5.  Malignancy and systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Ann Clarke; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

6.  Cytomegalovirus infection in pediatric rheumatic diseases: a review.

Authors:  Eli M Eisenstein; Dana G Wolf
Journal:  Pediatr Rheumatol Online J       Date:  2010-05-20       Impact factor: 3.054

Review 7.  Epstein-Barr virus and systemic lupus erythematosus.

Authors:  Anette Holck Draborg; Karen Duus; Gunnar Houen
Journal:  Clin Dev Immunol       Date:  2012-07-03

8.  Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus erythematosus patients.

Authors:  N S Rasmussen; A H Draborg; C T Nielsen; S Jacobsen; G Houen
Journal:  Scand J Rheumatol       Date:  2015-01-06       Impact factor: 3.641

9.  Reduced IgG anti-small nuclear ribonucleoprotein autoantibody production in systemic lupus erythematosus patients with positive IgM anti-cytomegalovirus antibodies.

Authors:  Claudia Azucena Palafox Sánchez; Minoru Satoh; Edward Kl Chan; Wendy C Carcamo; José Francisco Muñoz Valle; Gerardo Orozco Barocio; Edith Oregon Romero; Rosa Elena Navarro Hernández; Mario Salazar Páramo; Antonio Cabral Castañeda; Mónica Vázquez Del Mercado
Journal:  Arthritis Res Ther       Date:  2009-02-20       Impact factor: 5.156

10.  Elevated Concentrations of Serum Immunoglobulin Free Light Chains in Systemic Lupus Erythematosus Patients in Relation to Disease Activity, Inflammatory Status, B Cell Activity and Epstein-Barr Virus Antibodies.

Authors:  Anette H Draborg; Magnus C Lydolph; Marie Westergaard; Severin Olesen Larsen; Christoffer T Nielsen; Karen Duus; Søren Jacobsen; Gunnar Houen
Journal:  PLoS One       Date:  2015-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.